THE WOODLANDS, Texas, June 4, 2004 (PRIMEZONE) -- Power 3 Medical Products, Inc. (OTCBB:PWRM) announces today encouraging initial results from their recently formed research agreement with Baylor College of Medicine to search for biomarkers that directly impact the diagnosis of neurodegenerative diseases. The Company in collaboration with Stan Appel, M.D., Chairman of the Department of Neurology at Baylor College of Medicine, has completed the first phase of clinical validation, testing serum proteins from 79 patients, normal and neurodegenerative disease controls, including patients with Lou Gehrig's (ALS), Alzheimer's, and Parkinson's diseases.
Power 3, in collaboration with Dr. Appel and his team at Baylor, have applied the latest proteomic techniques to the differential diagnosis of neurodegenerative diseases utilizing blood serum. Dr. Stan Appel, a recognized global leader in neuromuscular and neurodegenerative disease research, has been working in concert with Power 3 and Dr. Ira L. Goldknopf, Chief Scientific Officer to further validate these biomarkers.
According to Dr. Ira Goldknopf, "With this test, which involves monitoring the concentration of 9 proteins in the blood, we are able to identify unique biomarkers whose profiles appear to distinguish patients with Lou Gehrig's (ALS), Alzheimer's, and Parkinson's diseases from each other as well as from normal patients and patients with other motor neuron and neurological disorders. To our gratification, the specificity and sensitivity of this test exceeded our expectations."
Dr. Stan Appel, commented, "These 9 proteins identified by Power 3 represent promising biomarkers for ALS, Alzheimer's and Parkinson's diseases. A main problem to date is that there is a lack of biomarkers for early diagnosis, prognosis, and guidelines for therapy for neurodegenerative diseases. We are pleased with the progress that has been made, and feel these biomarkers have great promise to improve the clinical outcomes of our patients."
The Company is proceeding with a confirmatory second phase involving serum from an additional 104 individuals with results expected shortly.
About Power 3 Medical Products, Inc.
Power 3 Medical Products is a leading-edge biotechnology company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases that the Company's proprietary technology can detect in patients. These discoveries are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. The Company is in a strong competitive position with over 190 validated biomarkers and operates a state-of-the-art proteomics laboratory in The Woodlands, Texas.
Safe Harbor Statement
All statements other than statements of historical fact included in this press release are "forward-looking statements." The forward-looking statements, including statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements (i.e., future operational results and sales) are subject to assumptions and beliefs based on current information known to the Company and factors that are subject to uncertainties, risk and other influences, which are outside the Company's control, and may yield results differing materially from those anticipated.